Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.08 Analyst target: $4.83 Upside: 346.76%
Cellectis SA, a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T cells that express chimeric antigen receptors to attack and eradicate cancer cells. The company is headquartered in Paris, France.
See the full interactive analysis & chart →Informational only — not investment advice.